Full Breakdown
Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of GLP-1 Drugs
7/21/2026, 10:35:59 PM
Core Event
On July 21, Novo Nordisk filed a complaint in the U.S. District Court for the District of New Jersey accusing rival Eli Lilly of false advertising. The Danish drugmaker alleges that Lilly’s nationwide ads for its obesity injection Zepbound and diabetes treatment Mounjaro compare the highest approved doses of those medicines with lower doses of Novo’s Wegovy and Ozempic, while omitting newer, higher-dose versions of Novo’s products.
Background & Context
Both companies dominate the rapidly expanding GLP-1 market, a class of injectable and oral drugs used for weight loss and type-2 diabetes. Novo Nordisk introduced Wegovy, the first approved obesity injection, before Lilly launched Zepbound, which later overtook Wegovy in U.S. sales. In March, the FDA approved a 7.2-mg dose of Wegovy that Novo says delivers weight-loss results comparable to Lilly’s products. The dispute arises as each firm promotes its own formulations through direct-to-consumer advertising, a practice permitted only in a few countries, including the United States.
Data & Statistics
- The lawsuit cites that Lilly’s ad campaign has been displayed more than 700 million times since a revised version was released in late April.
- Novo’s general counsel John Kuckelman notes that separate late-stage trials of the highest approved doses showed average weight loss of about 48 pounds for Zepbound and about 47 pounds for Wegovy.
- The SURMOUNT-5 trial, completed in 2024, compared 10 mg or 15 mg Zepbound with 1.7 mg or 2.4 mg Wegovy doses.
- Analysts estimate the U.S. obesity-drug market could be worth more than $100 billion by 2030.
- Following the filing, Novo Nordisk shares fell 2 % in afternoon trading, while Eli Lilly’s rose 0.5 %.
Official Statements & Responses
Novo Nordisk seeks a court order requiring Lilly to withdraw the advertisements and to run a corrective-advertising campaign. The company also says it will pursue a preliminary injunction if the ads are not voluntarily removed, and it is seeking damages that include profits attributable to the contested ads.
Eli Lilly responded that its advertisements are based on the results of the SURMOUNT-5 trial, describing the trial as the “gold standard” for head-to-head comparison.
Verbatim Quotes
- “We will continue to focus on the science and defend against this lawsuit vigorously.” — Novo Nordisk
- “As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions,” — John F. Kuckelman
What’s Next
Novo Nordisk indicated it will file for a preliminary injunction in the coming days to halt the ads while the case proceeds. The court’s decision on whether to require corrective advertising could shape how GLP-1 drugs are marketed in the United States.
